

BTIC FILE COPY

TOXICITY OF RED AND VIOLET DYES IN M18 GRENADES:
MUTAGENIC SCREENING OF THREE DYES FOR MARKER GRENADES IN THE
SALMONELLA REVERSION ASSAY AND THE L5178Y/TK+/- MOUSE LYMPHOMA ASSAY

Final Report

Prepared by
Martha M. Moore, Ph.D.¹, Larry Claxton, Ph.D.¹,
Virginia Houk¹, Gail M. Nelson², and Karen Harrington-Brock²

1 Genetic Toxicology Division
Health Effects Research Laboratory
U.S. Environmental Protection Agency
Research Triangle Park, North Carolina 27711

Environmental Health Research and Testing, Inc. P.O. Box 12199 Research Triangle Park, NC 27709

June 30, 1989

Supported by


U.S. Army Medical Research and Development Command Fort Detrick, Frederick, Maryland 21701-5012 U.S. Army Project Order No. 87PP7808 Project Officer: James Eaton

Performed by

Genetic Toxicology Division
Health Effects Research Laboratory
U.S. Environmental Protection Agency
Research Triangle Park, North Carolina 27711

Approved for public release; distribution unlimited

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.



TOXICITY OF RED AND VIOLET DYES IN M18 GRENADES:
MUTAGENIC SCREENING OF THREE DYES FOR MARKER GRENADES IN THE
SALMONELLA REVERSION ASSAY AND THE L5178Y/TK+/- MOUSE LYMPHOMA ASSAY

Final Report

Prepared by Martha M. Moore, Ph.D. 1 , Larry Claxton, Ph.D. 1 , Virginia Houk 1 , Gail M. Nelson 2 , and Karen Harrington-Brock 2

1 Genetic Toxicology Division
Health Effects Research Laboratory
U.S. Environmental Protection Agency
Research Triangle Park, North Carolina 27711

Environmental Health Research and Testing, Inc. P.O. Box 12199 Research Triangle Park, NC 27709

June 30, 1989

Supported by

U.S. Army Medical Research and Development Command Fort Detrick, Frederick, Maryland 21701-5012 U.S. Army Project Order No. 87PP7808 Project Officer: James Eaton

Performed by

Genetic Toxicology Division Health Effects Research Laboratory U.S. Environmental Protection Agency Research Triangle Park, North Carolina 27711


Approved for public release; distribution unlimited

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.

| SECURITY CLASSIFICATION OF THIS PAGE | | | | | |
|--|--|--------------------------------|----------------------------------|-------------|------------------------------------|
| REPORT | DOCUMENTATIO | N PAGE | | | Form Approved OMB No. 0704-0188 |
| 1a. REPORT SECURITY CLASSIFICATION | | 16. RESTRICTIVE MARKINGS | | | |
| Unclassified | | | | | |
| 2a. SECURITY CLASSIFICATION AUTHORITY | | | /AVAILABILITY OF or public re | | istribution |
| 2b. DECLASSIFICATION / DOWNGRADING SCHEDULE | | unlimited | | | |
| 4. PERFORMING ORGANIZATION REPORT NUMBER | R(S) | 5. MONITORING | ORGANIZATION RI | PORT NÚME | IER(S) |
| 60. NAME OF PERFORMING ORGANIZATION | 66. OFFICE SYMBOL | 7a. NAME OF MO | ONITORING ORGA | NIZATION | |
| Genetic Toxicology Division | (If applicable) | | Biomedical R t Laboratory | | and |
| 6c. ADDRESS (City, State, and ZIP Code) | <u> </u> | | ty, State, and ZIP C | | |
| Health Effects Research Laborat | ory | Fort Detr | • . | | |
| U.S. Environmental Protection A | | Frederick | , MD 21702-5 | 010 | |
| Research Triangle Park, NC 2771 | • | | , | | |
| Ba. NAME OF FUNDING/SPONSORING | 8b. OFFICE SYMBOL | 9. PROCUREMENT | T INSTRUMENT IDE | NTIFICATION | NUMBER |
| ORGANIZATION U.S. Army Medical Research & Development Command | (If applicable) RMI-S | Project Or | der No. 87PF | 7808 | |
| &c. ADDRESS (City, State, and ZIP Code) | | 10. SOURCE OF F | UNDING NUMBER | 5 | |
| Fort Detrick | | PROGRAM | PROJECT | TASK | WORKTUNIT |
| Frederick, MD 21702-5012 | | ELEMENT NO. | NO. | NO. | ACCESSION NO. |
| 11. TITLE (Include Security Classification) | | <u> </u> | <u> </u> | | |
| • | 1- W10 01- | | | | |
| Toxicity of Red and Violet Dyes | in MIS Grenades | S | | | |
| 12. PERSONAL AUTHOR(S) Moore, Martha Nelson, Gail M. ar | | | | IC) | |
| Final Report 13b. TIME Co | | 14. DATE OF REPO 1989 June | | Day) 15. P/ | AGE COUNT |
| 16. SUPPLEMENTARY NOTATION Mutagenic Salmonella Reversion Assay and | Screening of T | hree Dyes for | r M18 Marker | Grenade | s in the |
| Salmonella Reversion Assay and | | | | | |
| 17. COSATI CODES | 18. SUBJECT TERMS (| | | | |
| FIELD GROUP SUB-GROUP | M18 Smoke Gren | | | • . | |
| | Assay; Solvent RA 3 | ked 1; Dispe | erse ked 11; | Dispers | e blue 3; |
| | | | | | |
| Three dyes (Solvent Red 1, Disp | end identity by block ni erse Blue 3 and | <i>imber)</i> 1 Disparse Re | fay — | tested f | or mutagenicity |
| in the Salmonella reversion ass | av and the 1517 | SV/TK [†] /→ mous | e lumphoma | accav | These in vitro |
| assays were performed both with | and without exc | ngenous activ | vation provi | ded hv A | roclor induced |
| rat liver S9. In the salmonell | and without ext | Red I was r | nneitive wit | h S9 act | ivation in |
| strain TA100 and negative to qu | | | | | |
| conditions. Disperse Blue 3 wa | e poeitive with | S9 activati | on in strain | TA1537 | and negative |
| to questionship positive under | the other test | onditions | Dienerce Pe | | noeitive with |
| to questionably positive under the other test conditions. Disperse Red 11 was positive with | | | | | |
| S9 activation in strain TA102, but negative to weakly positive with the other strains and | | | | | |
| activation conditions. Both Disperse Blue 3 and Disperse Red 11 were positive both with and | | | | | tested without |
| without S9 activation in the mouse lymphoma assay. Solvent Red 1 could not be tested without | | | | | |
| activation. With S9 activation, it was weakly positive. | | | | | |
| · | | \wedge | - · <i>y</i> | | |
| | | In agent of the | \ | 204 | |
| 20. DISTRIBUTION / AVAILABILITY OF ABSTRACT UNCLASSIFIED/UNLIMITED SAME AS R | 9 7 □ 571¢ 04494 | 21. ABSTRACT SEC UNCLASSIF | 1 | LIKON | |
| 22a. NAME OF RESPONSIBLE INDIVIDUAL | PT. DTIC USERS | 22b. TELEPHONE (| | 22c. OFFIC | E SYMBOL |
| Mary Frances Bostian | | 301-663-732 | | SGRD-R | |

FOREWORD

All of the mutagenicity assays were performed in the Genetic Toxicology Division of the Health Effects Research Laboratory (HERL), U.S. Environmental Protection Agency (U.S. EPA), Research Triangle Park, NC. The Salmonella reversion assays were performed under the direction of Dr. Larry Claxton. The L5178Y/TK $^+$ mouse lymphoma assays were performed under the direction of Dr. Martha Moore. The experiments were performed by the U.S. EPA and Environmental Health Research and Testing (EHRT) personnel working within the EPA laboratory. EHRT provides research support to EPA under contract.



EXECUTIVE SUMMARY

Dyes are used by the military in M18 marker signaling grenades. A number of organic dyes are presently being evaluated for potential use in these grenades. In addition to engineering studies for their performance in the field, the U.S. Army is concerned with evaluating any potential health hazards that might result from personal contact with the dyes in the industrial setting. A part of this testing is the analysis of potential genetic toxicity.

Three dyes (Solvent Red 1, Disperse Blue 3, and Disperse Red 11) were tested for mutagenicity in the Salmonella reversion assay and the L5178Y/TK^{+/-} mouse lymphoma assay. These in vitro assays were performed both with and without exogenous activation provided by Aroclor-induced rat liver S9. In the Salmonella assay, Solvent Red 1 was positive with S9 activation in strain TA100 and negative to questionably positive in the other strains and activation conditions. Disperse Blue 3 was positive with S9 activation in strain TA1537 and negative to questionably positive under the other test conditions. Disperse Red 11 was positive with S9 activation in strain TA102, but negative to weakly positive with the other strains and activation conditions. Both Disperse Blue 3 and Disperse Red 11 were positive both with and without S9 activation in the mouse lymphoma assay. Disperse Red 1 could not be tested without activation. With S9 activation, it was weakly positive.

TABLE OF CONTENTS

| | Page |
|---|------------------|
| FOREWORD EXECUTIVE SUMMARY. LIST OF FIGURES. LIST OF TABLES. | 2 3 5 5 |
| INTRODUCTION | 6 |
| MATERIALS AND METHODS | 7 |
| Salmonella reversion assay | , 9 10 |
| RESULTS AND DISCUSSION | 14 |
| Salmonella reversion assay | 14 ^9 0 |
| CONCLUSIONS | 42 |
| LITERATURE CITED | 43 |
| DISTRIBUTION LIST | 45 |

LIST OF FIGURES

| | | Page |
|-----|---|------|
| 1. | Colony sizing for Solvent Red 1 with S9 | 35 |
| 2 . | Colony sizing for Disperse Blue 3 with S9 | 39 |
| 3. | Colony sizing for Disperse Red 11 with S9 | 42 |
| | LIST OF TABLES | |
| | | Page |
| 1. | Summary results of Army dyes tested in the <u>Salmonella</u> typhimurium mutagenicity assay | 15 |
| 2. | Salmonella typhimurium mutagenicity test results for Solvent Red 1 | 16 |
| 3. | Salmonella typhimurium mutagenicity test results for Disperse Blue 3 | 20 |
| 4. | Salmonella typhimurium mutagenicity test results for Disperse Red 11 | 25 |
| 5. | Qualitative summary of the TLC/Salmonella assay results for three Army dyes | 30 |
| 6. | Mouse lymphoma assay of Solvent Red 1 without metabolic activation | 32 |
| 7. | Mouse lymphoma assay of Solvent Red 1 with metabolic activation | 33 |
| 8. | Mouse lymphoma assay of Disperse Blue 3 without metabolic activation | 36 |
| 9. | Mouse lymphoma assay of Disperse Blue 3 with metabolic activation | 38 |
| 10. | Mouse lymphoma assay of Disperse Red 11 without metabolic activation | 40 |
| 11. | Mouse lymphoma assay of Disperse Red 11 with metabolic | 4.1 |

INTRODUCTION

Dyes are used by the military in M18 marker signaling grenades. A number of organic dyes are presently being evaluated for potential use in these grenades. In addition to engineering studies for their performance in the field, the U.S. Army is concerned with evaluating any potential health hazards that might result from personal contact with the dyes in the industrial setting. A part of this testing is the analysis of potential genetic toxicity.

Three dyes, Solvent Red 1, Disperse Blue 3, and Disperse Red 11 were tested for mutagenicity in the Salmonella reversion assay and the L5178Y/TK $^{+/-}$ mouse lymphoma assay. All three dyes were tested both with and without exogenous activation. In addition to testing in the "standard" Salmonella assay, all three dyes were also evaluated in the thin layer chromatography (TLC) modification.

MATERIALS AND METHODS

The dyes tested were: Solvent Red 1, Disperse Blue 3, and Disperse Red 11. Samples of these three dyes were supplied by the Army.

SALMONELLA REVERSION ASSAY

The procedures used were those of Maron and Ames (1983) with minor modifications. The guidelines of Claxton et al. (1987) were followed for both test performance and interpretation. Modifications are included in the description that follows. For each sample, the following six histidinerequiring strains were used: TA98, TA100, TA102, TA104, TA1537, and TA1538. The mechanisms by which each of these strains revert to prototrophy are fully discussed in other publications (Ames et al., 1975; Maron and Ames, 1983). In addition to these basic mechanisms, the reader should keep in mind the following salient points. These strains carry an rfa mutation which produces a deficiency in bacterial cell wall lipopolysaccharides and increases the cell's permeability to large molecules; the uvrB mutation decreases genetic repair; and the R-factor plasmid in strains TA98 and TA100 increases the spontaneous mutation rate. The six strains differ in the number of spontaneous revertants per plate generally found. Compounds which are known mutagens for the different strains, with and without activation, were included in each assay as positive controls. The retention of phenotypic characteristics was checked with each test by examining for histidine auxotrophy (lack of growth on histidine deficient medium), deep rough character (sensitivity to crystal violet on a disk), UV-repair deficiency (sensitivity to UV light), and the presence of the appropriate plasmid (resistance to ampleIllin on a disk).

Preparation of Rat Liver S9 Mix

Male CD-1 (Fisher derived) rats weighing approximately 200 g were given a single intraperitoneal injection of Aroclor 1254 in corn oil (200 mg/ml) at a dose of 50 mg/kg of body weight. One day prior to termination the animals were taken off food but provided water ad libitum. The livers were aseptically removed and washed in sterile cold 0.15 M KCl. All subsequent steps were performed at 0° to 4°C with cold sterile solutions and sterile glassware. The livers were minced with scissors in 0.15 M KCl (3 ml/g wet weight liver) and homogenized with a Potter-Elvehjem homogenizer. The homogenate was centrifuged for 10 min at 9000 x g, the supernatant (S9) decanted and stored in convenient aliquots at -80°C.

The S9 was mixed with a cofactor solution containing 8 mmol MgCl $_2$. 32 mmol KCl, 5 mmol glucose-6-phosphate, and 4 mmol nicotinamide adenine dinucleotide in 100 mmol of sodium phosphate buffer, pH 7.4. The final S9 mix contained between 0.05 and 0.1 ml S9/ml cofactor solution.

Test Procedure

For revertant selection, minimal Vogel-Bonner medium E supplemented with 1.5% Difco Bacto agar and 2% glucose was used for base agar layers. The top agar (0.6% Difco Bacto agar, 0.5% NaCl) was supplemented with minimal amounts of histidine and biotin. The bacterial broth culture (1- 2×10^9 viable cells per ml) and the test material dissolved in dimethylsulfoxide (DMSO) (supplied sterile, spectrophotometric grade) were added to the top agar. For tests without activation, 0.5 ml of cofactor solution was added instead of the S9 mix to the top agar. The plates were incubated in the dark at $37\,^{\circ}\text{C}$ for $72\,\text{hr}$. The plates were examined for background growth, and the number of colonies per plate were counted using an Artek 880 automatic colony counter.

Statistical Analyses

Statistical tests and computer programs used were those of Stead et al. (1981). This model assumes that revertant colony formation at any dose follows a Poisson process, while the mean number of revertants per plate is a nonlinear function of up to four parameters. The resultant system of nonlinear equations is solved using a modified Gauss-Newton iterative scheme to obtain maximum likelihood estimates of the model parameters. Significance of the key parameters was tested by fitting reduced models and using likelihood ratio tests.

The determination of positives was based on the following criteria:

- o The data must not vary significantly from a Poisson distribution (p > 0.01).
- o The data must be acceptable by the test of adequacy of fit of the model (p > 0.01).
- o The test for mutagenicity (the slope of the curve) must be significant (p < 0.01).
- o All positive and negative controls must have given expected responses as compared to HERL, U.S. EPA historical values and those published by Ames et al. (1975).
- o Histidine cross-feeding and/or contamination must not have been shown to occur.

The modeling of the bioassay provides a valuable aid to the researcher; however, each curve was (and needs to be) examined individually to assure confidence in the apparent conclusions of the statistical process. For example, if the dose-response data "fit" statistically a horizontal line (response vs. dose), the model will under some circumstances record a mutagenicity p-value less than 0.01; however, since the slope equals zero the response is negative.

An equivocal response occurs when (1) test results were not reproducible.

- (2) a 'ow-level but no dose-related increase in $\underline{\text{his}}$ colonies is obtained, or
- (3) when an increase was observed at only a single dose level. See the papers

by Ames et al., 1975; Claxton et al., 1987; and Maron and Ames, 1983 for further discussions of test result interpretation.

The reader must also keep in mind that these particular tests were reformed to maximize the chance of detecting a mutagenic response and not to provide comparative slope values. Examination of the data also shows that test doses were often adjusted due to results of a previous test. These adjustments obviously can shift results from a negative response to positive result (e.g. if a compound was initially tested at too low a dose-response range) and may alter the slope value (e.g. providing more doses in the central portion of the dose-response curve).

The minimum testing requirements were as follows:

- o A minimum of five doses at half-log intervals with the highest dose being highly toxic, as shown by background clearing and/or reduction in expected revertant counts per plate.
- o Spontaneous and positive controls done at least in duplicate and providing the expected response as compared to HERL, U.S. EPA historical values and those published by Ames et al. (1975).
- o Positive controls (in duplicate) for the microsomal activation combination used are within normal ranges as compared to HERL, U.S. EPA historical values and those published by Ames et al. (1975).
- o These minimum criteria are carefully explained in other publications (Ames et al., 1975; Claxton et al., 1987).

TLC/SALMONELLA ASSAY

Because the mutagenicity of technical-grade chemicals might arise from the presence of a contaminant, it is useful to have a rapid screening system to detect this possibility. A rapid, inexpensive system that was employed for this purpose is the TLC/Salmonella mutagenicity assay. With this system (Bjorseth et al., 1982), the sample is chromatographed on TLC plates, and the components for the Salmonella mutagenicity assay are applied directly to the developed chromatogram. The subsequent appearance of localized clusters of mutant colonies suggests the presence of a mutagenic constituent. This assay has been successfully applied to a number of different substances (Bjorseth et al., 1982; Moller et al., 1983; Houk and Claxton, 1986). The modification used for this study (Houk and Claxton, 1986) uses a single agar overlay poured over the TLC plate. This overlay contains the tester strain of bacteria and any exogenous activation system that is used.

Test Procedure and Analysis

Commercially available glass-backed silica or cellulose high performance thin layer chromatography (HPTLC) plates (10 cm \times 10 cm) are developed (without sample application) in absolute ethanol. After development they are dried at room temperature under the hood for 5 min, and then dried an additional 20 min at 80°C. Plates are subsequently treated as sterile.

Samples are then spotted on the plate via a micropipette in varying volumes, depending on their mutagenic potency. When possible, all dyes were spotted at concentrations ranging from 2 μg to 1 mg per spot. Samples are evenly spaced along the width of the plate 1.5 cm from the pottom; ordinarily four sample volumes are applied across the plate. Plates are then lowered into a developing tank containing the appropriate solvent system at a depth of 1 cm.

Chloroform is the first solvent applied. If chloroform does not separate the components of the sample, various other systems are tried. Samples can also be applied singly to a plate at a point 1.5 cm from the bottom and 1.5 cm from the left-hand side and run 2-dimensionally (with two different solvent systems) to further separate the constituent parts. In most instances, chloroform has proven sufficient.

The mobile phase is allowed to migrate up the plate at room temperature until the solvent front is about 1/2 cm from the top of the plate. Plates are then removed from the chamber and allowed to air dry under the hood.

At this point, plates are examined under UV light for fluorescent activity. Components may also be made visible on parallel plates by conventional techniques or examined under ambient light for the presence of additional patterns.

In order for the TLC plates to fit into the 150x150 mm disposable petri dishes, the upper two edges must be removed with the aid of a glass cutter. Plates are placed into the dishes with the developed side facing up. To 30 ml of VBME agar at 45°C are added 500 μl suspension (1x109 bacteria/ml) of the tester strain and 1.5 ml of S9 mix, when required. Contents are slowly poured into the space between the TLC plate and the edge of the petri dish, and the dish rotated for even distribution. The agar is allowed to harden, and the plates inverted and incubated at 37°C for 72 hours.

Plates are then examined for clusters of colonies, toxic zones, and/or total revertant count. If colonies are evenly spread across the TLC plate (for example, as seen with highly polar compounds), a total increase in mutant colonies is seen. In most cases, the increase in mutant colony numbers will be associated with the mutagenic constituent that has migrated during chromatography. Toxic components are characterized by a zone devoid of bacterial colonies.

L5178Y/TK+/- MOUSE LYMPHOMA ASSAY

Solvent Red 1, Disperse Blue 3, and Disperse Red 11 were evaluated for mutagenicity in the L5178Y/TK $^{+/-}$ mouse lymphoma assay using the procedures described by Turner et al. (1984). This in vitro mammalian system evaluates mutations affecting the thymidine kinase locus. This assay may be particularly useful in a test battery since the mutants quantitated can be divided, by colony size, into two distinct groups (small-colony and large-colony mutants). These two classes of mutants appear to reflect the relative clastogenic and mutagenic potential of the compound tested. Hozier et al.

(1981, 1983) have shown that the majority of small-colony mutants reflect chromosome damage affecting chromosome 11 (the location of the thymidine kinase gene), while large-colony mutants appear to represent small-scale, perhaps single-gene damage.

Cell Line and Cell Maintenance

The TK^{+/-} -3.7.2C heterozygote of L5178Y mouse lymphoma cells (supplied by Dr. Donald Clive) was utilized. This cell line was routinely grown in supplemented Fischer's Medium for Leukemic Cells of Mice (see below). Cells were monitored daily (except for weekends) for acceptable growth rates. For weekends, the cells were sufficiently diluted so that they would remain in log-phase growth; weekend cell doubling times were always determined. Weekly, prior to use in the assay, cells were cleansed of spontaneous $TK^{-/-}$ cells by 24-hr growth in the presence of thymidine (3 mg/ml), hypoxanthine (5 mg/ml), methotrexate (0.1 mg/ml), and glycine (7.5 mg/ml) (THMG). This was followed by 24-hr growth in THG (THMG minus methotrexate) medium. Stock cells were stored in liquid nitrogen.

Media

TK^{+/-} -3.7.2C cells were cultivated in Fischer's Medium for Leukemic Cells of Mice supplemented with 31 mg/ml penicillin (1650 units/mg), 50 mg/ml streptomycin sulfate, 0.1% Pluronic F68, 0.22 mg/ml sodium pyruvate (F0P), and 10% horse serum to make F10P. Medium was heat inactivated at 55°C for 45 minutes. Cells were cloned in the above described supplemented medium to solidify the cloning medium for colony formation. The selective agent used for mutation at the TK locus was 1 μ g/ml trifluorothymidin (TFT).

Preparation of Chemical Solutions

Concentrations were prepared on a weight per volume basis. DMSO was used as the solvent. A fresh stock of test material was used for each separate experiment.

Preparation of the Metabolic Activation System

Aroclor 1254-induced rat liver S9 was purchased from Sitek, Inc. who prepared it in the following manner: Rats weighing 200-300 g were injected intraperitoneally with a 2:1 mixture of Aroclor 1254 in corn oil (500 mg of total Aroclor/kg body weight). After 5 days the animals were sacrificed by CO2 exclusion of air. They were totally immersed in a solution of Wescodyne for approximately 3 seconds and their heads quickly excised. The livers were removed and placed in preweighed beakers containing 0.25 M sucrose. Livers were washed three times in 50-100 ml portions of cold 0.25 M surcose to yield 3 ml per gram of liver. Livers were minced and then homogenized in a blender for two 15-second periods. The homogenate was centrifuged at 9000 x g for 10 min at 4°C. The lipid layer was removed and discarded. The supernatant was pooled and aliquoted into sterile serum vials and placed directly into liquid nitrogen vapor phase containers for storage prior to shipping. A sterility check and activity test for standard promutagens in the mouse lymphoma assay were performed prior to shipping.

Upon receipt the S9 was stored at -70° C in a Revco freezer and tested for the ability to activate benzo(a)pyrene to mutagenic metabolites as based on induced mutant frequency in the standard mouse lymphoma assay.

The S9 mix was made in a 1:4 ratio of S9 to cofactor mix. Cofactor mix was made just prior to addition of S9 and consisted of F_0P (Fischer's Medium supplemented but without horse serum), 8 mg/ml B-nicotinamide adenine dinucleotide phosphate (NADP), and 15 mg/ml DL-isocitric acid trisodium salt (isocitrate). This solution was filter sterilized, mixed with freshly thawed S9, and kept on ice until used.

Mutagenicity Assay

The doses chosen for the mutagenicity assay were based on the results of a dose-ranging study. One 50-ml Corning polypropylene tube seeded with 6x106 cells in 6.0 ml of medium with a reduced amount of serum (5% instead of 10%) was used for each dose. Four ml of serum-free Fischer's medium (FOP) were added to each tube. The compound was dissolved in DMSO at 100 times the highest concentration to be tested. Sufficient solvent was added to each tube so that after addition of the test compound all tubes contained the same final solvent concentration. Normally 1% DMSO is the maximum used in this assay to deliver the test compound. The test compound was added to each appropriately labelled tube, the tubes were then regassed with 5% CO2-in-air and incubated in a roller drum at 37°C for 4 hr. Following the 4-hr exposure period, the tubes were centrifuged for 10 min at 200 x g and the supernatant containing the test compound was discarded. The cells were then washed twice in 10 ml of $F_{10}P$ (2 x 10 min centrifugations at 200 x g), and resuspended in 20 ml of fresh $F_{10}P$ to a final cell concentration of $3x10^5$ cells/ml. The tubes were regassed with 5% CO2-in-air and incubated in the roller drum at 37°C.

Positive control compounds were tested with each experiment. methanesulfonate (EMS, 400 μ g/ml) was used without exogenous activation, and benzo(a)pyrene (BAP, 3 and 4 μ g/ml) with S9 activation. Cell counts were determined with a Coulter Counter Model ZBI at 24 and 48 hr after exposure to the compound. Each culture was diluted daily to 2x105 cells/ml. At the end of 48 hr, the cells were cloned. Cloning allows for the selective growth and enumeration of mutant cells in a soft agar cloning medium (CM) and for the determination of cloning efficiency. Fifteen ml of each culture were spun in a centrifuge at 200 x g for 10 min and the supernatant decanted. Approximately 1-2 ml of $F_{10}P$ were added to each culture for resuspension of The cell pellet was vigorously resuspended to ensure a the cell pellet. single cell suspension and placed in 100 ml of CM to give a cell concentration of $3x10^4$ cells/ml. The flasks were labelled with the appropriate culture number and selective agent to be used (TFT). The cells were allowed to acclimate for 30 min and then a 1:50 dilution was made. (One ml was transferred from each culture to prelabelled flasks containing 50 ml of CM.) After mixing for 15 min, 1.0 ml from each 50-ml flask was transferred to 100 ml of CM and labelled with the culture number and viable count (VC) (cell concentration = 6 cells/ml). The selective agent, 1 mg/ml TFT, was added to the flasks containing $3x10^4$ cells/ml. Three petri plates per TFT and VC flask were poured, 33 ml per 100 mm petri plate. The plates were chilled at -20°C for 12 min, placed in a 5% CO_2 incubator, and incubated for 10-12 days at 37°C.

At the end of the incubation period the plates were scored for the number of colonies per plate using an Artek colony counter model 880. TFT- resistant colonies from selected cultures showing positive mutagenicity were sized by differential counts at periodic size discriminator settings. This information was expressed as histograms showing the relative proportions of small- and large-colony TFT-resistant mutants. This approach is a possible means of characterizing the type of mutagenic events occurring [i.e. single gene mutations (large colonies) or chromosomal aberrations affecting the TK and other genes (small colonies)].

Calculation of Mutant Frequency

The mutant frequency was calculated by divi ing the total number of mutant colonies for each culture by the number of viable cells plated for the culture (as determined by the VC plates). The spontaneous mutant frequency (solvent control) was subtracted from the total mutant frequency to give the induced mutant frequency.

Criteria for the Evaluation of the Results

The following criterion (based on the statistical methods of Clive et al., 1979) must be met to designate the test compound as a definite positive: One or more doses (from at least two separate assays) must show a significant increase in mutant frequency at reasonable (>10%) survival and there must be a multi-point dose-related response at adequate (>10% survival) cytotoxicities.

If there is no significant increase of the mutant frequency over background and if the compound has been adequately tested (with and without metabolic activation, reasonably spaced doses, adequate cytotoxicity-sufficient doses in the 10-20% survival range), then the results will be interpreted as negative.

The minimum criteria for an acceptable assay are: (1) plating efficiency of the solvent control is between 50 and 115%, (2) spontaneous mutant frequency of the solvent control is less than 100×10^6 and (3) positive controls show a definite positive response.

RESULTS AND DISCUSSION

SALMONELLA REVERSION ASSAY

The Salmonella bioassay is frequently used to screen substances for genotoxicity including potential carcinogenicity. The three dyes were tested in the standard plate incorporation assay using six strains supplied by Dr. Bruce Ames. The six strains used were TA98, TA100, TA102, TA104, TA1537, and TA1538. In addition, the three dyes were also tested using the TLC/Salmonella assay. A summary of the results is presented in Tables 1, 2, 3, and 4. The results are very heterogeneous.

For all three dyes, three of the strains, namely TA98, TA104, and TA1538, gave no positive responses either with or without exogenous metabolic activation. TA104 and TA1538, however, did provide a questionable response for Disperse Blue when exogenous activation was used. In addition, TA104 with exogenous activation gave a questionable response for Solvent Red 1. These questionable responses could not be resolved due to the dense coloration of the plates (which created enumeration difficulties and obscured precipitation when it occurred), the potential overlapping of toxicity and mutagenicity, and the limits of solubility of the dye. TA1537 gave a clearly positive response for the Disperse Blue dye when activation was used; however, TA1537 without activation did not give a definitive positive response. TA102 appeared to

TABLE 1. SUMMARY RESULTS OF ARMY DYES TESTED IN THE <u>SALMONELLA</u> <u>TYPHIMURIUM</u> MUTAGENICITY ASSAY*

| Test | Exog. | Solvent | Disperse | Disperse |
|-----------|-------|-----------|-----------|----------|
| Condition | Act. | Red 1 | Blue 3 | Red 11 |
| | | | | |
| TA100 | + | positive | negative | negative |
| TA100 | • | negative | negative | negative |
| TA1538 | + | negative | equivocal | negative |
| TA1538 | - | negative | negative | negative |
| TA98 | + | negative | negative | negative |
| TA98 | - | negative | negative | negative |
| TA1537 | + | negative | positive | negative |
| TA1537 | - | negative | equivocal | negative |
| TA102 | + | equivocal | weak pos. | positive |
| TA102 | - | negative | equivocal | weak pos |
| TA104 | + | equivocal | equivocal | negative |
| TA104 | - | negative | negative | negative |

^{*} See text and publications by Ames et al., 1975; Maron and Ames, 1983; and Claxton et al., 1987 for explanations on the determination of positive, negative, and equivocal responses. A "weak pos." means a weak positive and shows that no consistent response above twofold the spontaneous count was seen.

TABLE 2. SALMONELLA TYPHIMURIUM MUTAGENICITY TEST RESULTS FOR SOLVENT RED 1*

| DOSE | WITH ACTI | VATION | WITHOUT AC | TIVATION |
|----------|-------------|----------------|-------------|----------|
| µg/plate | <u>MEAN</u> | SD | <u>MEAN</u> | SD |
| | TA100 |) MARCH 22, 1 | 988 | |
| POS | 408 | 23 | 1132 | 25 |
| 0.0 | 132 | 21 | 150 | 5 |
| 0.3 | 139 | 1 | 195 | 15 |
| 3.0 | 192 | 4 | 142 | 3 |
| 30.0 | 231 | 8 | 152 | 10 |
| 300.0 | 195 | 15 | 129 | S |
| | TA100 |) APRIL 01, 1 | 988 | |
| POS | 576 | 36 | 470 | 2 |
| 0.0 | 121 | 11 | 119 | 22 |
| 0.3 | 120 | 16 | 138 | 10 |
| 3.0 | 159 | 19 | 141 | 11 |
| 10.0 | 193 | 11 | 141 | 14 |
| 30.0 | 196 | 15 | 133 | 14 |
| 100.0 | 192 | 21 | 132 | 13 |
| | TA100 | APRIL 11, 1 | 988 | |
| POS | 588 | 14 | 682 | 17 |
| 0.0 | 108 | 8 | 122 | 12 |
| 0.3 | 116 | 1 | 118 | 9 |
| 3.0 | 143 | 7 | 126 | 8 |
| 10.0 | 184 | 17 | 136 | 8 |
| 30.0 | 222 | 16 | 122 | 10 |
| 100.0 | 175 | 10 | 131 | 3 |
| | TA10 | 2 APRIL 22, 19 | 988 | |
| POS | 1418 | 427 | 1086 | 48 |
| 0.0 | 391 | 2 | 297 | 1 |
| 0.3 | 419 | 22 | 296 | 12 |
| 3.0 | 424 | 6 | 327 | 15 |
| 30.0 | 441 | 17 | 265 | 15 |
| 300.0 | 355 | 13 | 243 | 25 |
| | | | | 23 |

TABLE 2. (Continued)

| DOSE | WITH A | CTIVATION | WITHOUT AC | CTIVATION |
|----------|-------------|------------------|------------|-----------|
| µg/plate | <u>MEAN</u> | SD | MEAN | SD |
| | | m. 100 0 | | |
| | | TA102 MAY 2, 198 | 8 | |
| POS | 1219 | 21 | 1163 | 38 |
| 0.0 | 397 | 16 | 316 | 30 |
| 0.3 | 411 | 43 | 266 | 3 |
| 3.0 | 402 | 15 | 256 | 15 |
| 10.0 | 464 | 16 | 270 | 24 |
| 30.0 | 473 | 25 | 299 | 22 |
| 100.0 | 431 | 131 | 252 | 3 |
| | | TA102 MAY 6, 198 | 8 | |
| POS | 1227 | 41 | 905 | 33 |
| 0.0 | 386 | 16 | 260 | 18 |
| 0.3 | 493 | 17 | 285 | 9 |
| 3.0 | 470 | 12 | 274 | 17 |
| 10.0 | 498 | 1 | 285 | 23 |
| 30.0 | 473 | 8 | 272 | 14 |
| 100.0 | 506 | 15 | 289 | 21 |
| | T | A102 JULY 15, 19 | 88 | |
| POS | 949 | 72 | | |
| 0.0 | 234 | 22 | | |
| 50.0 | 242 | 19 | | |
| 100.0 | 244 | 47 | | |
| 200.0 | 167 | 14 | | |
| 300.0 | 203 | 17 | | |
| | TA | 104 APRIL 22, 19 | 988 | |
| POS | 681 | 7 | 536 | 33 |
| 0.0 | 337 | 34 | 263 | 4 |
| 0.3 | 379 | 4 | 349 | 103 |
| 3.0 | 871 | 567 | 1844 | 477 |
| 30.0 | 446 | 40 | 271 | 24 |
| 300.0 | 343 | 18 | 207 | 58 |
| | 1 | TA104 MAY 2, 198 | 8 | |
| POS | 732 | 31 | 484 | 14 |
| 0.0 | 287 | 24 | 261 | 12 |
| 0.3 | 280 | 16 | 259 | 3 |
| 3.0 | 339 | 18 | 248 | 14 |
| 10.0 | 337 | 22 | 233 | 17 |
| 30.0 | 361 | 14 | 268 | 14 |
| 100.0 | 350 | 30 | 233 | 23 |
| | | | _ | -3-2 |

TABLE 2. (Continued)

| DOSE | WITH AC | CTIVATION | WITHOUT AC | CTIVATION |
|----------|--|--------------------|-------------|-------------|
| μg/plate | MEAN | SD | <u>MEAN</u> | SD |
| | <u>, </u> | D. 10/ M. 17 6 10/ | | |
| |] | ra104 may 6, 198 | 38 | |
| POS | 781 | 23 | 595 | 14 |
| 0.0 | 341 | 30 | 265 | 3 |
| 0.3 | 309 | 12 | 243 | 4 |
| 3.0 | 368 | 21 | 238 | 12 |
| 10.0 | 420 | 30 | 236 | 20 |
| 30.0 | 452 | 13 | 265 | 14 |
| 100.0 | 379 | 23 | 252 | 19 |
| | TAI | 1537 APRIL 22, 1 | 1988 | |
| POS | 194 | 57 | 205 | 72 |
| 0.0 | 16 | 1 | 7 | 2 |
| 0.3 | 15 | 1 | 8 | 0 |
| 3.0 | 14 | 0 | 7 | 1 |
| 30.0 | 15 | 3 | 6 | ī |
| 300.0 | 9 | ĺ | 10 | 1 |
| | • | • | 10 | 1 |
| | T. | A1537 MAY 6, 19 | 88 | |
| POS | 292 | 20 | 254 | 93 |
| 0.0 | 15 | 3 | 7 | 1 |
| 0.3 | 18 | 2 | 9 | 4 |
| 3.0 | 19 | 6 | 9 | 7 |
| 10.0 | 14 | 2 | 7 | 2 |
| 30.0 | 23 | 5 | 11 | 5 |
| 100.0 | 14 | 6 | 7 | 1 |
| | TAl | .538 MARCH 22, 1 | .988 | |
| POS | | | 329 | 17 |
| 0.0 | | | 13 | <u> </u> |
| 0.3 | | | 15 | 0 |
| 3.0 | | | 10 | |
| 30.0 | | | 7 | 4 |
| 300.0 | | | 13 | 1 1 |
| | | | 13 | 1 |
| | TAl | 538 APRIL 01, 1 | 988 | |
| POS | 263 | 44 | 398 | 21 |
| 0.0 | 32 | 7 | 17 | 11 |
| 0.3 | 33 | 7 | 14 | 3 |
| 3.0 | 26 | 7 | 18 | 1 |
| 10.0 | 26 | 3 | 19 | 9 |
| 30.0 | 32 | 1 | 18 | 5 |
| 100.0 | 26 | 4 | 21 | 9 5 3 |
| | | | 2 | - |

TABLE 2. (Continued)

| | | WITHOUT AC | |
|-------|--|--------------------------|----------------------------|
| MEAN | SD | MEAN | SD |
| TA | 1538 APRIL 11, | L988 | |
| 0.2.5 | | | 1.0 |
| | | | 13 |
| | | | 5 |
| | | | 3 |
| | | | 6 |
| | | | 3 |
| | | | 1 4 |
| | | | - |
| T | A98 MARCH 22, 19 | 988 | |
| 335 | 30 | 207 | 23 |
| 40 | 1 | 36 | 10 |
| 37 | 4 | 17 | 5 |
| 52 | 3 | 29 | 8 |
| 34 | 4 | 19 | 3 |
| 42 | 6 | 26 | 6 |
| Т | A98 APRIL 1, 19 | 88 | |
| 456 | 3 | 248 | 17 |
| | | | 5 |
| | 6 | | 3 |
| 53 | 9 | 41 | 10 |
| 50 | 8 | 33 | 3 |
| 55 | 6 | 36 | 13 |
| 44 | 3 | 33 | 5 |
| T | A98 APRIL 11, 19 | 988 | |
| 360 | 7 | 181 | 37 |
| | | | 6 |
| | | | 6 |
| | | | 3 |
| 30 | 2 | 22 | 4 |
| 41 | 1 | 18 | 2 |
| 39 | 6 | | 7 |
| | TA 235 23 27 34 22 30 23 TA 335 40 37 52 34 42 TA 456 40 56 53 50 55 44 TA 360 27 37 36 30 41 | TA1538 APRIL 11, 12 235 | TA1538 APRIL 11, 1988 235 |

^{*} POS: Positive control compounds, which are: Sodium azide (3.0 μ g, TA100 and TA1535, -S9), 2-nitrofluorene (3.0 μ g, TA98 and TA1538, -S9), 9-aminoacridine (100 μ g, TA1537, -S9), 2-aminoanthracene (0.5 μ g, TA100 TA98, and TA1538, +S9) (3.0 μ g, TA104 and TA1537, +S9), dihydroxyanthraquinone (30.0 μ g, TA102, +S9), and methylglyoxal (50 μ g, TA104, -S9).

TABLE 3. SALMONELLA TYPHIMURIUM MUTAGENICITY TEST RESULTS FOR DISPERSE BLUE $3\star$

| DOSE | WITH AC | TIVATION | WITHOUT AC | TIVATION |
|----------|---------|------------------|------------|----------|
| μg/plate | MEAN | SD | MEAN | SD |
| | TA1 | LOO MARCH 22, 1 | 000 | |
| | INI | 100 MARON 22, 1 | 900 | |
| POS | 408 | 23 | 1132 | 25 |
| 0.0 | 132 | 21 | 150 | 5 |
| 3.0 | 140 | 3 | 149 | 4 |
| 30.0 | 155 | 5 | 143 | 8 |
| 300.0 | 116 | 2 | 135 | 15 |
| 3000.0 | 195 | 15 | 129 | 8 |
| | TAl | 00 APRIL 01, 1 | 988 | |
| POS | 576 | 36 | 470 | 2 |
| 0.0 | 121 | 11 | 119 | 22 |
| 3.0 | 137 | 9 | 133 | 4 |
| 10.0 | 162 | 6 | 134 | 11 |
| 30.0 | 140 | 6 | 134 | 3 |
| 100.0 | 123 | 18 | 141 | 3 |
| 300.0 | 109 | 14 | 128 | 15 |
| | TAI | .00 APRIL 11, 1 | 988 | |
| POS | 588 | 14 | 682 | 17 |
| 0.0 | 108 | 8 | 122 | 12 |
| 3.0 | 130 | 9 | 124 | 14 |
| 10.0 | 118 | 24 | 126 | 11 |
| 30.0 | 114 | 12 | 120 | 10 |
| 100.0 | 121 | 25 | 146 | 8 |
| 300.0 | 64 | 6 | 114 | 7 |
| | TA | 102 APRIL 22, 19 | 988 | |
| POS | 1418 | 427 | 1086 | 48 |
| 0.0 | 391 | 2 | 297 | 1 |
| 3.0 | 487 | 38 | 319 | 8 |
| 30.0 | 706 | 8 | 346 | 15 |
| 300.0 | 558 | 54 | 326 | 25 |
| 3000.0 | 141 | 9 | 102 | 8 |
| | | | | |

TABLE 3. (Continued)

| DOSE | WITH AC | CTIVATION | WITHOUT AC | CTIVATION |
|----------|---------|-----------------|------------|-----------|
| μg/plate | MEAN | SD | MEAN | SD |
| | _ | | | |
| | 7 | TA102 MAY 2, 19 | 88 | |
| POS | 1219 | 21 | 1163 | 38 |
| 0.0 | 397 | 16 | 316 | 30 |
| 3.0 | 298 | 16 | 289 | 16 |
| 10.0 | 345 | 21 | 270 | 24 |
| 30.0 | 387 | 27 | 299 | 22 |
| 100.0 | 418 | 32 | 252 | 3 |
| 300.0 | 380 | 43 | 316 | 30 |
| 500.0 | 300 | 45 | 210 | 30 |
| | ו | TA102 MAY 6, 19 | 88 | |
| POS | 1227 | 41 | 905 | 33 |
| 0.0 | 386 | 16 | 260 | 18 |
| 3.0 | 471 | 9 | 310 | 26 |
| 10.0 | 568 | 36 | 340 | 22 |
| 30.0 | 685 | 2 | 356 | 19 |
| 100.0 | 837 | 20 | 402 | 13 |
| 300.0 | 569 | 57 | 387 | 48 |
| | TA | A102 JULY 15, 1 | 988 | |
| POS | 876 | 51 | | |
| 0.0 | 142 | 19 | | |
| 25.0 | 239 | 14 | | |
| 50.0 | 234 | 17 | | |
| 100.0 | 247 | 17 | | |
| 200.0 | 287 | 15 | | |
| | 20. | 25 | | |
| | TA | 104 APRIL 22, 1 | .988 | |
| POS | 681 | 7 | 536 | 33 |
| 0.0 | 337 | 34 | 263 | 4 |
| 3.0 | 386 | 0 | 271 | 21 |
| 30.0 | 976 | 239 | 261 | 34 |
| 300.0 | 645 | 458 | 232 | 0 |
| 3000.0 | 124 | 11 | 183 | 46 |
| | 1 | ΓA104 MAY 2, 19 | 88 | |
| POS | 732 | 31 | 484 | 14 |
| 0.0 | 287 | 24 | 261 | 12 |
| | | | | |
| 3.0 | 280 | 17 | 222 | 9 |
| 10.0 | 305 | 4 | 253 | 24 |
| 30.0 | 261 | 12 | 241 | 21 |
| 100.0 | 259 | 68 | 256 | 6 |
| 300.0 | 100 | 2 | 208 | 23 |

TABLE 3. (Continued)

| DOSE | WITH AC | CTIVATION | WITHOUT A | CTIVATION |
|----------|--------------|------------------|-----------|-----------|
| μg/plate | <u>M</u> EAN | SD | MEAN | SD |
| | | 1.10/ | | |
| | 1 | CA104 MAY 6, 198 | 88 | |
| POS | 781 | 23 | 595 | 14 |
| 0.0 | 341 | 30 | 265 | 3 |
| 3.0 | 329 | 10 | 256 | 17 |
| 10.0 | 325 | 22 | 256 | 21 |
| 30.0 | 377 | 27 | 238 | 14 |
| 100.0 | 313 | 10 | 248 | 19 |
| 300.0 | 138 | 10 | 200 | 18 |
| | TAl | 537 APRIL 22, 1 | L988 | |
| POS | 194 | 57 | 205 | 72 |
| 0.0 | 16 | 1 | 7 | 2 |
| 3.0 | 17 | 4 | 10 | 5 |
| 30.0 | 32 | 2 | 9 | 0 |
| 300.0 | 65 | 3 | 9 | 1 |
| 3000.0 | 65 | 14 | 25 | 4 |
| | | T.4 | ۷.) | 4 |
| | TA | A1537 MAY 2, 19 | 88 | |
| POS | 254 | 24 | 116 | 22 |
| 0.0 | 15 | 3 | 9 | 5 |
| 3.0 | 25 | 6 | 7 | 4 |
| 10.0 | 44 | 5 | 11 | 3 |
| 30.0 | 49 | 10 | 13 | 4 |
| 100.0 | 102 | 7 | 14 | 3 |
| 300.0 | 123 | 14 | 18 | 3 |
| | TA | 1537 MAY 6, 19 | 88 | |
| POS | 292 | 20 | 254 | 93 |
| 0.0 | 15 | | 7 | 1 |
| 3.0 | 24 | 3 7 | 9 | 5 |
| 10.0 | 19 | 2 | 11 | 4 |
| 30.0 | 29 | 4 | 13 | 4 |
| 100.0 | 43 | 2 | 9 | 4 |
| 300.0 | 46 | 11 | 17 | 8 |
| | TA1 | | | |
| DOC | | , | | 4 |
| POS | | | 329 | 17 |
| 0.0 | | | 13 | 4 |
| 3.0 | | | 15 | 1 |
| 30.0 | | | 14 | 2 |
| 300.0 | | | 7 | 2 |
| 3000.0 | | | 11 | 2 |

TABLE 3. (Continued)

| DOSE | WITH | ACTIVATION | WITHOUT AC | CTIVATION |
|----------|------|---------------------|------------|-----------|
| μg/plate | MEAN | SD | MEAN | SD |
| | | TA1538 APRIL 01, 19 | 988 | |
| | | ,,,,, | | |
| POS | 263 | 44 | 398 | 21 |
| 0.0 | 32 | 7 | 17 | 11 |
| 3.0 | 37 | 4 | 15 | 0 |
| 10.0 | 49 | 5 | 20 | 4 |
| 30.0 | 65 | 7 | 22 | 7 |
| 100.0 | 60 | 10 | 12 | 3 |
| 300.0 | 43 | 2 | 13 | 2 |
| | | TA1538 APRIL 11, 19 | 988 | |
| POS | 235 | 16 | 339 | 13 |
| 0.0 | 23 | 7 | 13 | 5 |
| 3.0 | 32 | 5 | 12 | 3 |
| 10.0 | 59 | 5 | 14 | 9 |
| 30.0 | 72 | 4 | 13 | 4 |
| 100.0 | 66 | 7 | 17 | 1 |
| 300.0 | 46 | 4 | 13 | 5 |
| | | TA1538 JUNE 24, 19 | 88 | |
| POS | 713 | 25 | | |
| 0.0 | 25 | 4 | | |
| 0.5 | 26 | 4 | | |
| 1.0 | 23 | 6 | | |
| 3.0 | 31 | 1 | | |
| 5.0 | 32 | 6 | | |
| 10.0 | 33 | 3 | | |
| | | TA98 MARCH 22, 198 | 88 | |
| POS | 335 | 30 | 207 | 23 |
| 0.0 | 40 | 1 | 36 | 10 |
| 3.0 | 46 | 12 | 22 | 60 |
| 30.0 | 99 | 10 | 23 | 5 |
| 300.0 | 65 | 11 | 18 | 5 |
| 3000.0 | 28 | 7 | 15 | 1 |
| | | • | | - |

TABLE 3. (Continued)

| DOSE | WITH AC | TIVATION | WITHOUT AC | TIVATION |
|----------|---------|-----------------|------------|----------|
| μg/plate | MEAN | SD | MEAN | SD |
| | TA | .98 APRIL 1, 19 | 88 | |
| POS | 456 | 3 | 248 | 17 |
| 0.0 | 40 | 3 | 24 | 5 |
| 3.0 | 60 | 3 | 33 | 60 |
| 10.0 | 97 | 11 | 30 | 4 |
| 30.0 | 115 | 8 | 30 | 4 |
| 100.0 | 9.8 | 8 | 32 | 5 |
| 300.0 | 77 | 17 | 29 | 2 |
| | TA | 98 APRIL 11, 19 | 988 | |
| POS | 360 | 7 | 181 | 37 |
| 0.0 | 27 | 7 | 19 | 6 |
| 3.0 | 45 | 4 | 15 | 4 |
| 10.0 | 72 | 4 | 20 | 5 |
| 30.0 | 80 | 7 | 26 | 2 |
| 100.0 | 90 | 18 | 20 | 7 |
| 300.0 | 57 | 4 | 18 | 4 |

^{*} POS: Positive control compounds, which are: Sodium azide (3.0 μ g, TA100 and TA1535, -S9), 2-nitrofluorene (3.0 μ g, TA98 and TA1538, -S9), 9-aminoacridine (100 μ g, TA1537, -S9), 2-aminoanthracene (0.5 μ g, TA100, TA98, and TA1538, +S9) (3.0 μ g, TA104 and TA1537, +S9), dihydroxyanthraquinone (30.0 μ g, TA102, +S9), and methylglyoxal (50 μ g, TA104, -S9).

TABLE 4. SALMONELLA TYPHIMURIUM MUTAGENICITY TEST RESULTS FOR DISPERSE RED $11 \pm$

| WIIH A | CTIVATION | WITHOUT AC | TIVATION |
|-------------|---|---|---------------------------|
| <u>MEAN</u> | SD_ | MEAN | SD |
| TA | 100 MARCH 22, 1 | .988 | |
| 4.0.0 | | | 0.7 |
| | | | 25 |
| | | | 5 |
| | | | 14 |
| | | | 11 |
| | | | 9 |
| 88 | 9 | // | 19 |
| TA | 100 APRIL 01, 1 | 988 | |
| 576 | 36 | 470 | 2 |
| | | | 22 |
| | | | 10 |
| | | | 3 |
| | 6 | | 14 |
| | 30 | | 11 |
| 112 | 20 | 95 | 2 |
| TA | .100 APRIL 11, 1 | .988 | |
| 588 | 14 | 682 | 17 |
| | | | 12 |
| | | | 8 |
| | | | 15 |
| | | | 20 |
| | | | 8 |
| 98 | 11 | 87 | 11 |
| T | A102 APRIL 22, 1 | 988 | |
| 1/.19 | 1,27 | 1086 | 48 |
| | | | 1 |
| | | | 11 |
| | | | 16 |
| | | | 26 |
| 224 | 180 | 129 | 32 |
| | MEAN TA 408 132 158 159 112 88 TA 576 121 138 130 123 137 112 TA 588 108 118 130 127 140 98 TA 1418 391 525 577 474 | TA100 MARCH 22, 1 408 23 132 21 158 12 159 6 112 1 88 9 TA100 APRIL 01, 1 576 36 121 11 138 2 130 2 123 6 137 30 112 20 TA100 APRIL 11, 1 588 14 108 8 118 11 130 10 127 8 140 15 98 11 TA102 APRIL 22, 1 1418 427 391 2 525 29 577 30 474 230 | TA100 MARCH 22, 1988 408 |

TABLE 4. (Continued)

| DOSE | WITH A | CTIVATION | WITHOUT AC | TIVATION |
|----------|--------|------------------|------------|----------|
| μg/plate | MEAN | SD | MEAN | SD |
| | | | | |
| | 7 | TA102 MAY 2, 19 | 88 | |
| POS | 1219 | 21 | 1163 | 38 |
| 0.0 | 397 | 16 | 316 | 30 |
| 0.75 | 384 | 11 | 302 | 26 |
| 7.5 | 535 | 11 | 373 | 25 |
| 75.0 | 748 | 76 | 501 | 19 |
| 250.0 | 627 | 84 | 493 | 48 |
| 750.0 | 484 | 25 | 370 | 91 |
| | | ΓA102 MAY 6, 198 | 88 | |
| POS | 1227 | 4.1 | 0.05 | 2.2 |
| 0.0 | | 41 | 905 | 33 |
| 0.75 | 386 | 16 | 260 | 18 |
| | 410 | 11 | 283 | 23 |
| 7.5 | 499 | 2 | 327 | 11 |
| 75.0 | 624 | 22 | 377 | 12 |
| 250.0 | 619 | 31 | 360 | 2 |
| 750.0 | 319 | 55 | 345 | 37 |
| | TA | 104 APRIL 22, 1 | 988 | |
| POS | 681 | 7 | 536 | 33 |
| 0.0 | 337 | 34 | 263 | 4 |
| 7.5 | 339 | 33 | 287 | 4 |
| 75.0 | 382 | 27 | 271 | 30 |
| 750.0 | 315 | 14 | 215 | 9 |
| 7500.0 | 135 | 18 | 119 | 19 |
| | 1 | TA104 MAY 2, 198 | 38 | |
| POS | 732 | 31 | 484 | 14 |
| 0.0 | 287 | 24 | 261 | 12 |
| 0.75 | 279 | 18 | 226 | 7 |
| 7.5 | 318 | 15 | 233 | 14 |
| 75.0 | 265 | 12 | 219 | 8 |
| 250.0 | 209 | 17 | 151 | |
| 750.0 | 209 | 16 | 164 | 20 21 |
| | | TA104 MAY 6, 198 | | |
| | • | .M104 IMI 0, 170 | ,0 | |
| POS | 781 | 23 | 595 | 14 |
| 0.0 | 341 | 3C | 265 | 3 |
| 0.75 | 294 | 9 | 246 | 11 |
| 7.5 | 311 | 29 | 247 | 10 |
| 75.0 | 302 | 28 | 180 | 6 |
| 250.0 | 341 | 25 | 182 | 6 |
| 750.0 | 299 | 8 | 163 | 23 |
| | | | | |

TABLE 4. (Continued)

| DOSE | WITH AC | CTIVATION | WITHOUT AC | TIVATION |
|-------------|-----------|------------------|------------|-------------|
| µg/plate | MEAN | SD | MEAN | SD |
| | TAl | .537 APRIL 22, 1 | 988 | |
| POS | 194 | 57 | 205 | 72 |
| 0.0 | 16 | 1 | 7 | 2 |
| 7.5 | 9 | 4 | 9 | 5 |
| 75.0 | 27 | 8 | 6 | 4 |
| 750.0 | 18 | 4 | 8 | 3 |
| 7500.0 | 14 | 3 | 10 | 1 |
| | T | A1537 MAY 2, 198 | 38 | |
| POS | 254 | 24 | 116 | 22 |
| 0.0 | 15 | 3 | 9 | 5 |
| 0.75 | 15 | 0 | 11 | 5 |
| 7.5 | 18 | 2 | 12 | 7 |
| 7.3 75.0 | 10 | 5 | 10 | |
| 250.0 | 19 | 4 | | 2 |
| 750.0 | 22 | 6 | 10 14 | 5 3 5 |
| 730.0 | | | | J |
| | T | A1537 MAY 6, 198 | 38 | |
| 208 | 292 | 20 | 254 | 93 |
| 0.0 | 15 | 3 | 7 | 1 |
| 0.75 | 13 | 6 | 7 | 3 |
| 7.5 | 18 | 10 | 13 | 5 |
| 75.0 | 15 | 10 | 11 | 5 |
| 250.0 | 16 | 1 | 10 | 1 |
| 750.0 | 15 | 4 | 14 | 6 |
| | TA1 | 538 MARCH 22, 1 | 988 | |
| POS | | | 329 | 17 |
| 0.0 | | | 13 | 4 |
| 7.5 | | | 12 | 5 |
| 75.0 | | | 10 | |
| 750.0 | | | 9 | 5 |
| 7500.0 | | | 4 | 5 5 3 |
| | TAl | .538 APRIL 01, 1 | 988 | |
| POS | 263 | 44 | 398 | 21 |
| 0.0 | 32 | 7 | 17 | 11 |
| 0.75 | 29 | 3 | 11 | 3 |
| 7.5 | 36 | 3 | 10 | 4 |
| 75.0 | 44 | 5 | 16 | |
| 250.0 | 36 | 12 | 12 | 5 5 |
| 750.0 | 39 | 8 | 12 | 2 |
| 730.0 | <i>.,</i> | U | 1.6 | <u> </u> |

TABLE 4. (Continued)

| DOSE | WITH A | CTIVATION | WITHOUT AC | CTIVATION |
|----------|--------|------------------|------------|-----------|
| μg/plate | MEAN | SD | MEAN | SD |
| | TA | 1538 APRIL 11, 1 | 1988 | |
| POS | 235 | 16 | 339 | 13 |
| 0.0 | 23 | 7 | 13 | 5 |
| 0.75 | 90 | 34 | 12 | 4 |
| 7.5 | 48 | 5 | 8 | 3 |
| 75.0 | 40 | 4 | 20 | 6 |
| 250.0 | 48 | 17 | 12 | 4 |
| 750.0 | 49 | 11 | 14 | 8 |
| | TA1 | 538 AUGUST 19, | 1988 | |
| POS | 287 | 24 | | |
| 0.0 | 26 | 7 | | |
| 0.5 | 24 | 3 | | |
| 1.0 | 31 | 7 | | |
| 3.0 | 24 | 5 | | |
| 5.0 | 22 | 3 | | |
| 10.0 | 34 | 2 | | |
| | TA | A98 MARCH 22, 19 | 988 | |
| POS | 335 | 30 | 207 | 23 |
| 0.0 | 40 | 1 | 36 | 10 |
| 7.5 | 66 | 11 | 25 | 7 |
| 75.0 | 81 | 11 | 20 | 5 |
| 750.0 | 57 | 2 | 19 | 3 |
| 7500.0 | 16 | 2 | 13 | 4 |
| | Т | A98 APRIL 1, 19 | 88 | |
| POS | 456 | 3 | 248 | 17 |
| 0.0 | 40 | 3 | 24 | 5 |
| 0.75 | 55 | 6 | 32 | 6 |
| 7.5 | 77 | 11 | 33 | 5 |
| 75.0 | 111 | 30 | 32 | 4 |
| 250.0 | 91 | 5 | 36 | 5 |
| 750.0 | 76 | 10 | 25 | 4 |
| | | | | |

TABLE 4. (Continued)

| DOSE | WITH ACTIV | VATION | WITHOUT ACT | IVATION |
|----------|------------|----------------|-------------|---------|
| ug/plate | MEAN | SD_ | MEAN | SD |
| | TA98 | APRIL 11, 1988 | | |
| POS | 360 | 7 | 181 | 37 |
| 0.0 | 27 | 7 | 19 | 6 |
| 0.75 | 37 | 7 | 20 | 1 |
| 7.5 | 57 | 8 | 25 | 8 |
| 75.0 | 65 | 6 | 17 | 3 |
| 250.0 | 86 | 4 | 22 | 1 |
| 750.0 | 80 | 18 | 18 | 1 |

^{*} POS: Positive control compounds, which are: Sodium azide (3.0 ug, TA100 and TA1535, -S9), 2-nitrofluorene (3.0 μ g, TA98 and TA1538, -S9), 9-aminoacridine (100 μ g, TA1537, -S9), 2-aminoanthracene (0.5 μ g, TA100, TA98, and TA1538, +S9) (3.0 μ g, TA104 and TA1537, +S9), dihydroxyanthraquinone (30.0 μ g, TA102, +S9), and methylglyoxal (50 μ g, TA104, -S9).

respond to all three dyes; however, the response of TA102 to Solvent Red 1 and Disperse Blue could only be classified as either a questionable or weak positive. The lack of clarity in TA102 results was due to the aforementioned difficulties in testing these dyes and to the high spontaneous counts typically seen with this tester strain. Solvent Red 1 was positive in TA100 when exogenous metabolic activation was used.

TLC/SALMONELLA ASSAY

The TLC/Salmonella procedure was used to confirm the plate incorporation protocol results, to examine for the presence of significant amounts of contaminants, and to determine (if contaminants were present) whether or not any mutagenicity was associated with the minor constituents. Except for Disperse Blue, the dyes chromatographed with starting spot concentrations ranging from 2 $\mu \rm g$ per spot to 1 mg per spot. Due to solubility problems, the highest concentration of Disperse Blue that could be applied was 600 $\mu \rm g$. Tests were done with Salmonella typhimurium tester strains TA98, TA100, TA1535, and TA1537. Testing was independent of the plate incorporation tests that were done with the same dyes. A summary of results is given in Table 5.

TABLE 5. QUALITATIVE SUMMARY OF THE TLC/SALMONELLA ASSAY RESULTS FOR THREE ARMY DYES

| Condition Examined | Solvent Red 1 | Disperse Blue 3 | Disperse Red 11 |
|---|---|---|---|
| Chromatography | | | |
| a. White light | red; single band | blue; two bands | purple |
| b. UV light | bright orange; single band | none | pink-orange; extra band at origin |
| Mutagenicity | | | |
| TA100+ TA100- TA98+ TA98- TA1537+ TA1537- TA1535+ TA1535- | Negative Negative Negative Negative Negative Negative Negative Negative | Negative Negative ? Negative Negative Positive Positive Negative Negative | Negative Negative Negative Negative Negative Negative Negative Negative |

Solvent Red 1

The single band resulting from this chromatographed dye was a bright red color under normal light. When examined under UV light, these streaks (which migrated with the solvent front) fluoresced a bright orange. This dye was negative in all four strains both with and without exogenous activation. At the higher doses, slight toxicity was observed when this dye was tested without activation.

Disperse Blue 3

At the lowest concentrations, only a single blue band was apparent on the developed TLC plate. At higher concentrations, two separate blue bands became apparent at the solvent front. At the highest concentrations, the sample streaked from the origin to the solvent front. This dye was not mutagenic in strains TA100 and TA1535 either with or without activation. Using TA1537, the dye was mutagenic both with and without S9. Without S9 activation, the dye demonstrated more than a twofold increase in the average number of revertants per plate. At the lower doses a slight cluster effect was seen; however, the cluster effect was more evident at higher doses. For an explanation of how to interpret this qualitative test, see the section on Test Procedure and Analysis and the paper by Houk and Claxton, 1986. With S9, the response was even more pronounced. This dye gave a slightly elevated increase (of approximately 40%) in the average number of TA98 revertant colonies per plate; however, with S9, no cluster effect was seen.

Disperse Red 11

Under normal light the visible bands and streaks were a purple color. Under long-wave UV light, the streaks fluoresced a pink-orange color; however, this fluorescent color was less apparent at concentrations above 200 μg due to the sample being such a deep purple. The developed bands were approximately 5 mm behind the solvent front. Also, at the point of origin, a fluorescent pink-orange circle with a dark purple leading segment was seen. This dye appeared negative in the four strains used both with and without exogenous metabolic activation.

L5178Y/TK+/- MOUSE LYMPHOMA ASSAY

In experiment 1 of the Solvent Red 1 series (Table 6), cells were treated with the chemical in the absence of S9 activation up to 10 $\mu g/ml$. Ideally in an experiment, the chemical will induce either a mutant frequency \geq 2X that of the negative controls or a toxic response in which one or more dosed points has a relative total growth between 10 and 20%. Because no positive responses were obtained and dosed points outgrew the negative controls, experiment 1 resulted in a "no test."

The maximum solubility of Solvent Red 1 was determined to be 3 mg/ml in DMSO. In experiment 2 (Table 6), cells were dosed up to 60 μ g/ml. All points tested were delivered in 200 μ l DMSO, and no precipitate was observed. The highest doses did not induce sufficient cytotoxicity, and the trial was

TABLE 6. MOUSE LYMPHOMA ASSAY OF SOLVENT RED 1 WITHOUT METABOLIC ACTIVATION

| | Relative | | | Relative | Relative | 1 |
|------------------------------|------------|--------|--------|------------|----------|-----------|
| Concentration | Suspension | Total | Total | Cloning | Total | Mutant |
| $(\mu g/ml)$ | Growth | viable | Mutant | Efficiency | Growth | Freg |
| | (%) | Clones | Clones | (%) | (%) | $(x10^6)$ |
| Experiment 1 | | | | | | |
| Neg. Control | 100 | 507 | 185 | 100 | 100 | 73 |
| Neg. Control | 100 | 525 | 146 | 100 | 100 | 56 |
| Pos. Control | | | | | | |
| (EMS 400 μ g/m | 1) 61 | 336 | 1850 | 65 | 40 | 1101 |
| 1 | 109 | 581 | 755 | 113 | 123 | 60 |
| 5 | 100 | 595 | 152 | 115 | 115 | 51 |
| 10 | 115 | 458 | 178 | 89 | 102 | 78 |
| Experiment 2 | | | | | | |
| Neg. Control Pos. Control | 100 | 447 | 155 | 100 | 100 | 69 |
| (EMS 400 μg/π | 1) 64 | 288 | 1848 | 61 | 39 | 1283 |
| 30 | 89 | 387 | 115 | 87 | 77 | 59 |
| 40 | 90 | 408 | 187 | 91 | 82 | 92 |
| 50 | 90 | 497 | 162 | 111 | 100 | 65 |
| 60 | 87 | 525 | 187 | 117 | 103 | 71 |

determined to be a "no test." Due to the lack of cytotoxicity at the maximum level of solubility, Solvent Red 1 could not be successfully evaluated without activation.

S9 activation elevated the induced mutant frequency and the cytotoxicity of the Solvent Red 1 (Table 7). Although no positive points occurred in the first experiment, an increase in mutant frequency appeared at doses greater than 6.1 μ g/ml. In the second experiment, the chemical was weakly positive (slightly greater than 2X background) at doses of 8.7 μ g/ml and higher. In the third experiment, all doses of 7.5 μ g/ml or higher induced a weakly positive mutagenic response. It should be noted that concentrations used in these experiments were very close together and the resultant dose-response curve shows a plateau response. When the TFT-resistant mutants were analyzed for the induction of small- and large-colony mutants (Figure 1), it was clear that neither type of mutant predominated.

Cells treated with Disperse Blue 3 exhibited a positive response without exogenous activation (Table 8) in two separate experiments. The chemical went into solution in DMSO, but formed a separate, lower layer when added to media. After vortexing, the chemical was soluble in the media. All centrifuge tubes

TABLE 7. MOUSE LYMPHOMA ASSAY OF SOLVENT RED 1 WITH METABOLIC ACTIVATION

| - | Relative | | | Relative | Relative | 1 |
|--------------------|------------|--------|--------|------------|----------|--------|
| Concentration | Suspension | Total | Total | Cloning | Total | Mutant |
| $(\mu g/m1)$ | Growth | viable | Mutant | Efficiency | Growth | Freq |
| | (%) | Clones | Clones | (%) | (%) | (x106) |
| n | | | | | | |
| Experiment 1 | | | | | | |
| Neg. Control | 100 | 511 | 188 | 100 | 100 | 74 |
| Neg. Control | 100 | 506 | 181 | 100 | 100 | 72 |
| Pos. Control | 7.0 | 207 | 764 | 2.0 | | |
| (BAP 3 μ g/ml) | | 307 | 756 | 80 | 57 | 372 |
| (BAP 4 μ g/ml) | 35 | 269 | 1079 | 53 | 18 | 802 |
| 4.0 | 90 | 546 | 230 | 107 | 97 | 84 |
| 5.0 | 80 | 533 | 248 | 105 | 84 | 93 |
| 5.3 | 79 | 479 | 239 | 94 | 74 | 100 |
| 5.6 | 71 | 469 | 223 | 92 | 66 | 95 |
| 5.8 | 69 | 504 | 213 | 99 | 68 | 85 |
| 6.1 | 65 | 482 | 305 | 95 | 62 | 127 |
| 6.5 | 62 | 498 | 250 | 98 | 61 | 100 |
| 6.75 | 29 | 479 | 286 | 94 | 28 | 119 |
| 7.0 | 58 | 478 | 276 | 94 | 54 | 115 |
| 7.5 | 42 | 453 | 274 | 81 | 37 | 121 |
| 8.0 | 30 | 432 | 281 | 85 | 26 | 130 |
| Experiment 2 | | | | | | |
| Neg. Control | 100 | 499 | 193 | 100 | 100 | 77 |
| Neg. Control | 100 | 548 | 210 | 100 | 100 | 77 |
| Pos. Control | | | | | | |
| (BAP 3 μ g/ml) | 84 | 505 | 792 | 96 | 81 | 314 |
| (BAP 4 μ g/ml) | 55 | 397 | 1091 | 76 | 41 | 560 |
| 5.7 | 83 | 562 | 244 | 107 | 89 | 87 |
| 6.1 | 81 | 520 | 272 | 99 | 81 | 105 |
| 6.5 | 72 | 544 | 264 | 104 | 75 | 97 |
| 6.75 | 73 | 508 | 282 | 97 | 71 | 111 |
| 7.0 | 71 | 584 | 263 | 112 | 79 | 90 |
| 7.3 | 58 | 527 | 289 | 101 | 58 | 110 |
| 7.5 | 57 | 538 | 348 | 103 | 59 | 129 |
| 8.0 | 46 | 510 | 338 | 97 | 45 | 132 |
| 8.2 | 31 | 496 | 395 | 100 | 31 | 152 |
| 8.5 | 32 | 565 | 380 | 108 | 34 | 134 |
| 8.7 | 28 | 497 | 511 | 95 | 27 | 206 |
| 8.9 | 25 | 456 | 404 | 87 | 22 | 177 |
| 9.0 | 16 | 459 | 468 | 88 | 14 | 204 |

TABLE 7. Continued

| | Relative | | | Relative | Relative | |
|--------------------|------------|--------|--------|------------|----------|--------|
| Concentration | Suspension | Total | Total | Cloning | Total | Mutant |
| $(\mu g/ml)$ | Growth | viable | Mutant | Efficiency | Growth | Freq |
| | (%) | Clones | Clones | (%) | (%) | (x106) |
| Experiment 3 | | | | | | |
| Neg. Control | 100 | 500 | 228 | 100 | 100 | 91 |
| Neg. Control | 100 | 469 | 190 | 100 | 100 | 81 |
| Pos. Control | | | | | | |
| (BAP 3 μ g/ml) | 72 | 337 | 847 | 70 | 50 | 503 |
| (BAP 4 μ g/ml) | 30 | 272 | 1059 | 56 | 17 | 779 |
| 5.3 | 73 | 487 | 265 | 101 | 73 | 109 |
| 6.1 | 60 | 447 | 294 | 92 | 55 | 132 |
| 6.7 | 52 | 460 | 259 | 95 | 49 | 113 |
| 7.3 | 44 | 444 | 347 | 92 | 40 | 156 |
| 7.5 | 39 | 346 | 312 | 74 | 28 | 180 |
| 8.0 | 26 | 411 | 354 | 85 | 22 | 172 |
| 8.3 | 24 | 394 | 389 | 81 | 20 | 197 |
| 8.4 | 20 | 400 | 349 | 83 | 17 | 174 |
| 8.5 | 19 | 367 | 426 | 76 | 14 | 232 |
| 8.6 | 19 | 356 | 343 | 73 | 14 | 193 |
| 8.7 | 17 | 341 | 412 | 70 | 12 | 242 |
| 8.8 | 17 | 423 | 416 | 87 | 15 | 197 |
| 8.9 | 16 | 418 | 352 | 86 | 14 | 222 |
| 9.0 | 13 | 317 | 335 | 65 | 9 | 211 |
| 9.1 | 12 | 415 | 423 | 86 | 10 | 204 |

SOLVENT RED 1 WITH S9




Figure 1. Colony sizing for TFT-resistant mutants following Solvent Red 1 treatment of mouse lymphoma cells with S9 metabolic activation. The small colonies are represented on the left side of size setting 250 on the histogram. The large colonies are to the right of size setting 250.

TABLE 8. MOUSE LYMPHOMA ASSAY OF DISPERSE BLUE 3 WITHOUT METABOLIC ACTIVATION

| | Relative | | | Relative | Relative | |
|---------------------|------------|--------|--------|------------|----------|--------|
| Concentration | Suspension | Total | Total | Cloning | Total | Mutant |
| $(\mu g/m1)$ | Growth | viable | Mutant | Efficiency | Growth | Freq |
| | (%) | Clones | Clones | (%) | (%) | (x106) |
| Experiment 1 | | | | | | |
| Neg. Control | 100 | 498 | 110 | 100 | 100 | 44 |
| Neg. Control | 100 | 445 | 137 | 100 | 100 | 62 |
| Pos. Control | | | | | | |
| (EMS 400 μ g/ml | .) 64 | 288 | 1848 | 61 | 39 | 1283 |
| 15 | 74 | 461 | 246 | 98 | 72 | 107 |
| 45 | 47 | 416 | 345 | 88 | 42 | 166 |
| 50 | 40 | 452 | 372 | 96 | 39 | 165 |
| 55 | 46 | 441 | 293 | 94 | 43 | 133 |
| 60 | 45 | 339 | 301 | 110 | 50 | 116 |
| 65 | 37 | 495 | 305 | 105 | 39 | 123 |
| 70 | 38 | 401 | 291 | 85 | 32 | 145 |
| 75 | 27 | 428 | 350 | 91 | 25 | 164 |
| Experiment 2 | | | | | | |
| Neg. Control | 100 | 460 | 196 | 100 | 100 | 85 |
| Neg. Control | 100 | 438 | 148 | 100 | 100 | 68 |
| Pos. Control | | | | | | |
| (EMS 400 μg/ml | .) 72 | 365 | 1556 | 72 | 59 | 853 |
| 15 | 87 | 442 | 307 | 97 | 85 | 139 |
| 30 | 63 | 500 | 371 | 110 | 70 | 148 |
| 60 | 46 | 444 | 364 | 98 | 45 | 164 |
| 70 | 35 | 392 | 395 | 86 | 31 | 202 |
| 80 | 36 | 383 | 461 | 84 | 31 | 241 |
| 90 | 39 | 353 | 474 | 79 | 31 | 269 |
| 100 | 24 | 282 | 479 | 63 | 15 | 340 |

and media were stained dark blue post-treatment. Cell pellets remained stained after rinsing with fresh media at all doses greater than 5 $\mu g/ml$.

S9 activation (Table 9) increased the magnitude of the mutant frequency induced by Disperse Blue 3 treatment. Once again, the compound stained cell pellets and media dark blue. Microscopic examination of supernatant obtained from day 1 dilutions indicated the presence of a chemical precipitate in both experiments at doses of 60 μ g/ml or higher. These cultures were discarded, and results were not obtained for doses greater than 55 μ g/ml. An examination of the colony sizing curves indicates that Disperse Blue 3 induced both small-and large-colony mutants with small-colony mutants predominating (Figure 2). This indicates that Disperse Blue 3 is likely acting by a clastogenic mechanism (Moore et al., 1985; Doerr et al., 1989).

Disperse Red 11 was clearly mutagenic without S9 activation at all doses \geq 5 $\mu g/ml$ (Table 10). The chemical went into solution in DMSO at 75 mg/ml. Post-treatment observation of the first experiment indicated that cell pellets were dyed red at all doses of 5 $\mu g/ml$ or higher. By microscopic analysis, these cells appeared swollen, and centrifuge tubes were stained at all doses \geq 15 $\mu g/ml$. Cell debris remained present on day 1 at 20 and 25 $\mu g/ml$. On day 1 of the second experiment, cells dosed at 25 $\mu g/ml$ or higher remained dyed red. Microscopic observation indicated no crystals were present.

Disperse Red 11 was also positive with exogenous activation (Table 11). Supernatant from the wash and day 1 dilutions of both experiments were examined under the microscope for chemical precipitate. In the first experiment, large amounts of debris were present at all doses greater than 45 $\mu \mathrm{g/ml}$. As a result, these points were discarded. Although debris was present in the second experiment and cells remained stained at doses of 40 $\mu \mathrm{g/ml}$ and greater, the debris were present in smaller quantities, appeared to consist of dead cells, and no crystals were observed. Disperse Red 11 induced both small- and large-colony mutants, indicating no preference for single gene or chromosomal mutations (Figure 3).

TABLE 9. MOUSE LYMPHOMA ASSAY OF DISPERSE BLUE 3 WITH METABOLIC ACTIVATION

| | Relative | | | Relative | Relative | |
|--------------------|------------|--------|--------|------------|----------|--------|
| Concentration | Suspension | Total | Total | Cloning | Total | Mutant |
| $(\mu g/ml)$ | Growth | viable | Mutant | Efficiency | Growth | Freq |
| | (%) | Clones | Clones | (%) | (%) | (x106) |
| Experiment 1 | | | | | | |
| Neg. Control | 100 | 482 | 164 | 100 | 100 | 68 |
| Neg. Control | 100 | 518 | 205 | 100 | 100 | 79 |
| Pos. Control | | | | | | |
| (BAP 3 μ g/ml) | 86 | 488 | 645 | 98 | 84 | 264 |
| $(BAP 4 \mu g/ml)$ | 51 | 491 | 1010 | 98 | 50 | 411 |
| 1 | 97 | 525 | 227 | 105 | 101 | 87 |
| 5 | 92 | 528 | 430 | 106 | 97 | 163 |
| 10 | 84 | 444 | 550 | 89 | 74 | 248 |
| 15 | 84 | 491 | 631 | 98 | 82 | 257 |
| 30 | 68 | 395 | 852 | 79 | 54 | 431 |
| 40 | 51 | 369 | 901 | 74 | 38 | 488 |
| 45 | 39 | 351 | 858 | 70 | 27 | 489 |
| 50 | 31 | 320 | 809 | 64 | 19 | 506 |
| 55 | 23 | 282 | 857 | 56 | 13 | 608 |
| Experiment 2 | | | | | | |
| Neg. Control | 100 | 496 | 180 | 100 | 100 | 73 |
| Neg. Control | 100 | 537 | 224 | 100 | 100 | 83 |
| Pos. Control | | | | | | |
| (BAP 3 μ g/ml) | 83 | 423 | 677 | 82 | 68 | 320 |
| (BAP 4 μ g/ml) | 63 | 457 | 929 | 88 | 55 | 407 |
| 5 | 78 | 487 | 364 | 94 | 74 | 149 |
| 15 | 79 | 491 | 678 | 95 | 75 | 276 |
| 30 | 62 | 316 | 813 | 61 | 38 | 515 |
| 45 | 45 | 276 | 1070 | 53 | 24 | 575 |

DISPERSE BLUE 3 WITH S9




Figure 2. Colony sizing for TFT-resistant mutants following Disperse Blue 3 treatment of mouse lymphoma cells with S9 metabolic activation. The small colonies are represented on the left side of size setting 250 on the histogram. The large colonies are to the right of size setting 250.

TABLE 10. MOUSE LYMPHOMA ASSAY OF DISPERSE RED 11 WITHOUT METABOLIC ACTIVATION

| | Relative | | | Relative | Relative | |
|--------------------|------------|------------------|------------------|----------------|------------|----------------|
| Concentration | Suspension | Total | Total | Cloning | Total | Mutant |
| $(\mu g/ml)$ | Growth (%) | viable Clones | Mutant Clones | Efficiency (%) | Growth (%) | Freq (x106) |
| | | | | | | |
| Experiment 1 | | | | | | |
| Neg. Control | 100 | 498 | 110 | 100 | 100 | 44 |
| Neg. Control | 100 | 445 | 137 | 100 | 100 | 62 |
| Pos. Control | | | | | | |
| (EMS 400 μ g/n | n1) 64 | 288 | 1848 | 61 | 39 | 1283 |
| 5 | 87 | 338 | 366 | 72 | 62 | 217 |
| 10 | 82 | 372 | 340 | 79 | 64 | 183 |
| 15 | 67 | 389 | 398 | 82 | 55 | 205 |
| 20 | 65 | 335 | 356 | 71 | 46 | 212 |
| 25 | 69 | 348 | 315 | 74 | 51 | 181 |
| Experiment 2 | | | | | | |
| Neg. Control | 100 | 460 | 196 | 100 | 100 | 85 |
| Neg. Control | 100 | 438 | 148 | 100 | 100 | 68 |
| Pos. Control | nl) 72 | 365 | 1556 | 81 | 59 | 853 |
| (EMS 400 μg/m | 11) /2 | 303 | 0001 | 01 | 39 | 803 |
| 1 | 86 | 463 | 159 | 103 | 89 | 69 |
| 5 | 64 | 349 | 489 | 78 | 50 | 280 |
| 10 | 59 | 328 | 641 | 73 | 43 | 390 |
| 15 | 73 | 382 | 344 | 85 | 62 | 179 |
| 20 | 72 | 378 | 399 | 84 | 60 | 211 |
| 25 | 72 | 340 | 470 | 76 | 54 | 276 |
| 30 | 71 | 386 | 436 | 85 | 61 | 226 |
| 35 | 71 | 377 | 446 | 83 | 59 | 237 |
| 40 | 68 | 356 | 429 | 59 | 41 | 241 |

TABLE 11. MOUSE LYMPHOMA ASSAY OF DISPERSE RED 11 WITH METABOLIC ACTIVATION

| | Relative | { | | Relative | Relative | |
|------------------------------|------------|--------|--------|------------|----------|--------|
| Concentration | Suspension | Total | Total | Cloning | Total | Mutant |
| $(\mu g/m1)$ | Growth | viable | Mutant | Efficiency | Growth | Freq |
| | (%) | Clones | Clones | (%) | (%) | (x106) |
| Experiment 1 | | | | | | |
| Neg. Control | 100 | 496 | 180 | 100 | 100 | 73 |
| Neg. Control | 100 | 537 | 224 | 100 | 100 | 83 |
| Pos. Control | | , | | 200 | 200 | 0.3 |
| (BAP 3 μ g/ml) | 83 | 423 | 677 | 82 | 68 | 320 |
| (BAP 4 μ g/ml) | 63 | 457 | 929 | 88 | 55 | 407 |
| 5 | 78 | 527 | 309 | 102 | 80 | 117 |
| 15 | 75 | 491 | 369 | 95 | 71 | 150 |
| 30 | 69 | 418 | 391 | 81 | 56 | 187 |
| 45 | 55 | 345 | 491 | 67 | 37 | 285 |
| Experiment 2 | | | | | | |
| Neg. Control | 100 | 588 | 233 | 100 | 100 | 79 |
| Neg. Control Pos. Control | 100 | 517 | 207 | 100 | 100 | 80 |
| (BAP 3 μ g/ml) | 66 | 280 | 788 | 51 | 34 | 563 |
| (BAP 4 μ g/ml) | | 226 | 1204 | 41 | 9 | 1065 |
| 1 | 101 | 468 | 205 | 85 | 85 | 88 |
| 5 | 94 | 485 | 314 | 88 | 82 | 129 |
| 15 | 87 | 504 | 371 | 91 | 80 | 147 |
| 25 | 85 | 504 | 370 | 91 | 78 | 147 |
| 30 | 78 | 516 | 469 | 93 | 73 | 182 |
| 35 | 85 | 471 | 439 | 85 | 72 | 186 |
| 40 | 79 | 496 | 406 | 90 | 71 | 164 |
| 45 | 84 | 489 | 392 | 88 | 74 | 160 |
| 50 | 76 | 444 | 493 | 80 | 61 | 222 |
| 55 | 71 | 502 | 445 | 91 | 65 | 177 |
| 60 | 66 | 345 | 515 | 62 | 41 | 299 |
| 65 | 69 | 442 | 493 | 80 | 55 | 223 |

DISPERSE RED 11 WITH S9 50 r 50 UG/ML FREQUENCY X 10-35 UG/ML MUTANT 60 UG/ML

Figure 3. Colony sizing for TFT-resistant mutants following Disperse Red 11 treatment of mouse lymphoma cells with S9 metabolic activation. The small colonies are represented on the left side of size setting 225 on the histogram. The large colonies are to the right of size setting 225.

SIZE SETTING

CONCLUSIONS

All three of the dyes tested gave a positive response to one of the six Ames tester strains. These positive responses were only observed in the presence of metabolic activation. The positive responses in the bacterial test system indicate that these compounds are capable of inducing point mutations. This mutagenicity was confirmed by the mouse lymphoma assay data. Because of its insolubility, Solvent Red 1 could not be tested without metabolic activation in the mouse lymphoma assay, but was testable and was weakly positive with activation. Colony sizing analysis indicated an induction of both single gene and chromosomal mutations. Disperse Blue 3 was more mutagenic when tested with rather than without S9 activation. Many of these mutants appeared to result because of the clastogenicity of Disperse Blue 3. Disperse Blue 3 is structurally similar to another anthraquinone dye, Disperse Blue 7, that is a potent mutagen to mouse lymphoma cells (Harrington-Brock et al., in press). The genotoxicity of Disperse Red 11 was approximately the same both with and without S9. Colony sizing indicated that both single gene and chromosomal mutations were induced.

In summary, all three of the tested dyes have the ability to induce mutations both in bacteria and in mammalian cells.

LITERATURE CITED

- 1. Ames, B.N., J. McCann, and E. Yamasahi. 1975. Methods of detecting carcinogens and mutagens with the Salmonella/mammalian microsome mutagenicity test. <u>Mutat</u>. <u>Res</u>. 31:347-364.
- 2. Bjorseth, A., G. Eidsa, J. Gether, L. Landmark, and M. Moller. 1982. Detection of mutagens in complex samples by the Salmonella assay applied directly on thin layer chromatography plates. <u>Science</u> 215:87-89.
- 3. Claxton, L.D., J. Allen, A. Auletta, R. Mortelmans, E. Nestmann, and E. Zeiger. 1987. Guide for the <u>Salmonella typhimurium</u>/mammalian microsome tests for mutagenicity. <u>Mutat</u>. <u>Res</u>. 189:83-91.
- 4. Clive, D., K.O. Johnson, J.F.S. Spector, A.G. Batson, and M.M.M. Brown. 1979. Validation and characterization of the L5178Y/TK^{+/-} mouse lymphoma mutagen assay system. <u>Mutat</u>. <u>Res</u>. 59:61-108.
- 5. Doerr, C.L., K.H. Brock, and M.M. Moore. 1989. Micronucleus, chromosome aberration, and small-colony TK mutant analysis to quantitate chromosomal damage in L5178Y mouse lymphoma cells. <u>Mutat. Res.</u> 222:191-203.
- 6. Harrington-Brock, K., L. Parker, C. Doerr, M.C. Cimino, and M.M. Moore. Analysis of The Genotoxicity of Anthraquinone Dyes in the Mouse Lymphoma Assay. <u>Mutagenesis</u>, in press.
- 7. Houk, V.S., and L. Claxton. 1986. Screening complex hazardous wastes for mutagenic activity using a modified version of the TLC/Salmonella assay. <u>Mutat</u>. <u>Res</u>. 169:81-92.
- 8. Hozier, J., J. Sawyer, M. Moore, B. Howard, and D. Clive. 1981. Cytogenetic analysis of the L5178Y/TK+/- TK-/- mouse lymphoma mutagenesis assay system. <u>Mutat</u>. <u>Res</u>. 84:169-181.
- 9. Hozier, J., J. Sawyer, D. Clive, and M.M. Moore. 1983. Cytogenetic analysis of small-colony L5178Y TK-/- mutants early in their clonal history. In G.M. Williams, V.C. Dunkel, and V.A. Ray, eds. <u>Cellular Systems for Toxicity Testing pp.</u> 423-425. The New York Academy of Sciences, New York, N.Y.
- 10. Maron, D., and B. Ames. 1983. Revised methods for the Salmonella mutagenicity test. $\underline{\text{Mutat}}$. Res. 105:1-77.
- 11. Moller, M., A. Bjorseth, and V. Houk. 1983. Chemical separation and in situ mutagenicity testing. In H. Zimmerman and Taylor-Mayer, eds.

 Mutagenicity Testing in Environmental Pollution Control. Ellis Horwood Ltd., West Sussex, England.
- 12. Moore, M.M., D. Clive, J. Hozier, B.E. Howard, A.G. Batson, N.T. Turner, and J. Sawyer. 1985. Analysis of trifluorothymidine-resistant (TFT^r) mutants of L5178Y/TK^{+/-} mouse lymphoma cells. <u>Mutat</u>. <u>Res</u>. 151:161-174.

- 13. Stead, A.G., V. Hasselblad, J.P. Creason, and L. Claxton. 1981. Modeling the Ames Test. <u>Mutat</u>. <u>Res</u>. 85:13-27.
- 14. Turner, N.T., A.G. Batson, and D. Clive. 1984. Procedures for the L5178Y/TK+/- -> TK-/- mouse lymphoma assay. In B.J. Kilbey et al., eds. <u>Handbook of Mutagenicity Test Procedures</u>, pp. 239-268. Elsevier, Amsterdam.

DOCUMENT DISTRIBUTION LIST

No. of Copies 1 Commander US Army Medical Research and Development Command ATTN: CMI-S Fort Detrick Frederick, MD 21702-5012 2 Defense Technical Information Center (DTIC) ATTN: DTIC-DDA Cameron Station Alexandria, VA 22314 1 Dean School of Medicine Uniformed Services University of the Health Sciences 4301 Jones Bridge Road Bethesda, MD 20014 1 Commandant Academy of Health Sciences, US Army ATTN: AHS-COM Fort Sam Houston, TX 78234 26 Commander US Army Biomedical Research and Development Laboratory ATTN: SGRD-UBZ-C Fort Detrick Frederick, MD 21702-5010